Glycogen synthase kinase-3β gene is associated with antidepressant treatment response in Chinese major depressive disorder

Pharmacogenomics Journal

Volumn 8, Issue 6, 2008, Pages 384-390

  Tsai, S J ^a,b   Liou, Y J ^a,b,c,d   Hong, C J ^a,b   Yu, Y W Y ^e   Chen, T J ^f  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e Yu's Psychiatric Clinic   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CYTOSINE; FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3BETA; GUANOSINE; SEROTONIN UPTAKE INHIBITOR; THYMIDINE;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL;

ADULT; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHINA; DEPRESSIVE DISORDER, MAJOR; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3; HAPLOTYPES; HUMANS; MIDDLE AGED; PHARMACOGENETICS; SEROTONIN UPTAKE INHIBITORS;

EID: 55449087175     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500486     Document Type: Article

References (22)

1. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102.
2. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001; 7: 1321-1327.
3. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004; 29: 1426-1431.
4. Roh MS, Eom TY, Zmijewska AA, De Sarno P, Roth KA, Jope RS. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol Psychiatry 2005; 57: 278-286.
5. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
6. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
7. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: Implication in the treatment of bipolar disorder. Biol Psychiatry 2007; 61: 216-222.
8. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4: 183-194.
9. Mai L, Jope RS, Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 2002; 82: 75-83.
10. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 2004; 55: 781-784.
11. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 387-390.
12. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007; 61: 240-245.
13. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
14. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115-1119.
15. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
16. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005; 58: 829-839.
17. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: A review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002; 5: 255-275.
18. Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004; 368: 123-126.
19. Russ C, Lovestone S, Powell JF. Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol Psychiatry 2001; 6: 320-324.
20. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001; 2: 91-99.
21. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM et al Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51: 723-732.
22. Burke WJ, Hendricks SE, McArthur-Campbell D, Jacques D, Stull T. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. Psychopharmacol Bull 1996; 32 27-32.